- Pfizer forms licensing agreement with Seattle Genetics
- FDA approves Novartis drug for high blood pressure treatment
- FDA approves Merck's Gardasil for prevention of anal cancer
- New alliance will crack down on adulterated products touting dietary supplement claims
- Merck's hepatitis C drug granted priority review by FDA
NEW YORK — The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.
Pfizer and EMD Serono announced the approval of Rebif Rebidose (interferon beta-1a), a single-use auto-injector for self-administering Rebif, used to treat relapsing forms of MS. EMD Serono is the U.S. division of German drug maker Merck KGaA, so-named to avoid confusion with U.S.-based Merck & Co.
"We are pleased to announce the FDA has approved Rebif Rebidose, which provides people living with relapsing MS another option to meet their injection needs," EMD Serono president James Hoyes said. "The introduction of Rebif Rebidose underscores our commitment to the MS community and to our investment in the development of delivery devices to assist with ease of use and support those living with MS."